1. Comparability of clinical trials and spontaneous reporting data regarding COVID-19 vaccine safety;Luo;Sci Rep,2022
2. Pharmacovigilance Risk Assessment Committee (PRAC) PRAC recommendations on signals. Adopted at the 29 November-2 December 2021 PRAC meeting. European Medicines Agency 6 January 202Contract No.: EMA/PRAC/683817/2021.
3. Vaccine-induced immune thrombotic thrombocytopenia;Klok;LancetHaematol,2022
4. Pharmacovigilance Risk Assessment Committee (PRAC) Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 Vaccine (ChAdOx1-S [recombinant]) – COVID-19 Vaccine AstraZeneca (Other viral vaccines) [10 January 2023]. EMA/PRAC/157045/2021]. Available from: https://www.ema.europa.eu/en/documents/prac-recommendation/signal-assessment-report-embolic-thrombotic-events-smq-covid-19-vaccine-chadox1-s-recombinant-covid_en.pdf.
5. Pharmacovigilance Risk Assessment Committee (PRAC) EMA. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 24 - 27 October 2022 [10 January 2023]. Available from: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-24-27-october-2022.